Icatibanto Fresenius

Icatibant, the active ingredient in Icatibanto Fresenius, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with this rare genetic condition. GNH USA supplies Icatibanto Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibanto Fresenius acts on the bradykinin pathway to treat hereditary angioedema. - Hereditary angioedema type I: provides rapid reduction of swelling during acute attacks. - Hereditary angioedema type II: alleviates pain and tissue edema associated with an attack. - Bradykinin‑mediated angioedema: offers symptom relief when bradykinin is the primary trigger.

Icatibanto Fresenius may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reaction. - Nausea: transient gastrointestinal upset. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe hypotension: sudden drop in blood pressure. - Thrombocytopenia: reduced platelet count requiring monitoring.

Prior to prescribing Icatibanto Fresenius, clinicians should consider several safety aspects. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; weigh maternal benefit against infant risk. - Renal impairment: no dosage adjustment required, but monitor for accumulation. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced edema. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibanto Fresenius can interact with other medicines that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may worsen angioedema. - Angiotensin receptor blockers: similar risk of increased bradykinin. - Other bradykinin B2 antagonists: combined pharmacologic effect may be excessive.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may alter frequency of HAE attacks. - NSAIDs: can exacerbate edema or gastrointestinal irritation.